SCHEMBL23744711

SCHEMBL23744711

C[C@@H]1CN(c2ncc3ccccc3n2)[C@@H](C)CN1C(=O)NC1CCN(Cc2ccccc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 10/20 0.47
DPP7 Q9UHL4 1/20 0.47
CHRM1 P11229 4/20 0.46
CHRM2 P08172 4/20 0.46
CHRM3 P20309 3/20 0.46
PRKAB2 O43741 1/20 0.46
PRKAG1 P54619 1/20 0.46
PRKAA2 P54646 1/20 0.46
PRKAA1 Q13131 1/20 0.46
PRKAG3 Q9UGI9 1/20 0.46
PRKAG2 Q9UGJ0 1/20 0.46
PRKAB1 Q9Y478 1/20 0.46
CHRM5 P08912 1/20 0.46
SIGMAR1 Q99720 2/20 0.45
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44
DRD3 P35462 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23744565 0.90 CCR3 (0.49) CHRM4SIGMAR1
SCHEMBL23744718 0.88 CHRM4 (0.59) CHRM4CHRM1CHRM2CHRM3CHRM5
SCHEMBL26086704 0.87 HCAR2 (0.39) CHRM4CHRM1CHRM2CHRM3CHRM5
SCHEMBL23744548 0.85 HCAR2 (0.58) CHRM4DPP7CHRM1CHRM2PRKAB2
SCHEMBL23744503 0.84 CHRM4 (0.59) CHRM4CHRM1CHRM2CHRM3PRKAA2
SCHEMBL23744502 0.84 CHRM4 (0.59) CHRM4CHRM1CHRM2CHRM3PRKAA2
SCHEMBL23744245 0.84 CHRM2 (0.60) CHRM4CHRM1CHRM2CHRM3CHRM5
SCHEMBL23744508 0.84 CHRM2 (0.60) CHRM4CHRM1CHRM2CHRM3CHRM5
SCHEMBL23744110 0.84 CHRM4 (0.59) CHRM4CHRM1CHRM2CHRM3PRKAA2
SCHEMBL23744721 0.84 CHRM4 (0.60) CHRM4CHRM1CHRM2CHRM3CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
WO-2021158698-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE CHRM4, CHRM2, CHRM5 CHRM4 1/4885DPP7 2145/4885CHRM1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.